Zentalis Pharmaceuticals Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 02 2025
0mins
Source: Globenewswire
Stock Options Granted: Zentalis Pharmaceuticals announced the grant of non-qualified stock options for 381,000 shares to six newly hired employees as part of their 2022 Employment Inducement Incentive Award Plan, with an exercise price of $1.72 per share.
Company Overview: Zentalis is a clinical-stage biopharmaceutical company focused on developing azenosertib, a WEE1 inhibitor for ovarian cancer and other tumor types, which has shown promise in clinical trials for its anti-tumor activity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
